Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

NCT04881032 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT04881032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04881032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
Lead sponsor
Centre Jean Perrin
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 7, 2022
Completion date
March 31, 2027
Enrollment
66 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma